Meta-analysisindependent cross-checkabstract checked I-SUP-114 in-depth review

Omega-3 capsules: does dose matter?

Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis.

Overview

Rizos EC et al.. Heart 2021 · PMID 32820013 · DOI 10.1136/heartjnl-2020-316780

At the usual dose of one capsule a day, omega-3 had no effect on heart outcomes; higher doses might help, but evidence is weak.

Does the study support the specific claim? Partly · Methodological quality: high

Study explained simply

What did the researchers want to find out?: To see whether omega-3 effects depend on dose.
How was the study done?: Meta-analysis of double-blind trials by dose.
How many people, animals or samples were studied?: 17 trials, 83,617 people.
What was actually found?: No effect at <=1 g/day; possible benefit at 2-4 g/day.
How large was the observed effect?: Cardiac death RR 0.82 (0.68-0.99) at >=3 g/day.
What do the results mean in everyday life?: Ordinary fish-oil capsules do not protect the heart.
What are the study's limitations?: Few high-dose trials.
What does it say about Elawady's specific claim?: Supports C-SUP-05 for ordinary capsules.
Do the results apply to Germany and Europe?: Applicable.
What can explicitly not be concluded from this study?: Cannot confirm benefit of high doses.

Authors: Rizos EC et al.
Journal: Heart
Year: 2021
Identifier: PMID 32820013 DOI 10.1136/heartjnl-2020-316780
Verification: verified – PubMed efetch 2026-10-26; Crossref works API 2026-10-26
Retracted: no
Corrections: none
Extent checked: abstract only
Conflicts of interest and funding: COI statement in record: Competing interests: None declared.

Is omega-3 supplementation, by dose, associated with CVD outcomes?

Study design: Meta-analysis – Systematic review and meta-analysis of double-blind RCTs (>=1 year) stratified by dose, with trial sequential analysis
Population: Participants in double-blind omega-3 RCTs
Country: Multinational
Period: Not stated in abstract
Sample size: 17 studies; 83,617 participants
Inclusion and exclusion criteria: Double-blind RCTs, duration >=1 year

Exposure / intervention: Omega-3 capsules (<1, 1, 2, >=3 g/day)
Comparator: Placebo
Endpoints: All-cause mortality, cardiac death, sudden death, MI, stroke
Statistical methods: Stratified random-effects meta-analysis; trial sequential analysis

Results: <=1 capsule/day: no association with any outcome; futility boundaries crossed for all-cause mortality and cardiac death. 2 capsules/day: cardiac death RR 0.55 (0.33-0.90; 3 trials). >=3 capsules/day: cardiac death RR 0.82 (0.68-0.99), sudden death RR 0.70 (0.51-0.97; 1 trial), stroke RR 0.74 (0.57-0.95; 2 trials).
Absolute risks: not reported in abstract
Authors' conclusion: Omega-3 at <2 g capsules/day showed no association with CVD outcomes, unlikely to change with future research; evidence for 2-4 g/day is weak and needs replication.

Futility reached for low doses; high-dose findings rest on few trials.

Strong support that typical capsules (<=1 g/day) do not prevent CVD; limits the claim for high-dose prescription EPA.

High-dose findings (REDUCE-IT).

Applicable.

Best dose-stratified evidence; confirms the claim for ordinary capsules.

Multidimensional assessment
Multidimensional assessment
Authenticity of the source	verified
Methodological quality	high
Risk of bias	low
Precision of results	moderate
Directness	direct
Reproducibility	replicated
Consistency with the overall evidence	consistent
Regional transferability	high
Adequacy of the interpretation (by the archive)	not applicable

Replication of high-dose effects.